FR2549051B1
(fr)
|
1983-06-22 |
1986-05-16 |
Centre Nat Rech Scient |
Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
|
US5262319A
(en)
|
1985-04-19 |
1993-11-16 |
Oncogene Science, Inc. |
Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
|
US5583103A
(en)
|
1988-06-28 |
1996-12-10 |
La Jolla Cancer Research Foundation |
Inhibition of transforming growth factor beta activity
|
US5705609A
(en)
|
1988-06-28 |
1998-01-06 |
La Jolla Cancer Research Foundation |
Decorin fragments inhibiting cell regulatory factors
|
AU633011B2
(en)
|
1988-06-28 |
1993-01-21 |
La Jolla Cancer Research Foundation |
Suppression of cell proliferation by decorin
|
US5654270A
(en)
|
1988-06-28 |
1997-08-05 |
La Jolla Cancer Research Foundation |
Use of fibromodulin to prevent or reduce dermal scarring
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
JPH0780780B2
(ja)
|
1989-09-29 |
1995-08-30 |
ラ ホヤ キャンサー リサーチ ファウンデーション |
細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
|
DK0502036T3
(da)
|
1989-11-22 |
1996-05-06 |
Genentech Inc |
Latens-associeret peptid og anvendelser herfor
|
WO1991010727A1
(en)
|
1990-01-22 |
1991-07-25 |
La Jolla Cancer Research Foundation |
Inhibitors of cell regulatory factors
|
US5554655A
(en)
|
1991-09-30 |
1996-09-10 |
Jess G. Thoene |
Method of treating HIV infection
|
WO1993009228A1
(en)
|
1991-10-31 |
1993-05-13 |
Whitehead Institute For Biomedical Research |
TGF-β TYPE RECEPTOR cDNAS AND USES THEREFOR
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
EP1230929A1
(en)
|
1991-11-14 |
2002-08-14 |
La Jolla Cancer Research Foundation |
Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
|
GB9205800D0
(en)
|
1992-03-17 |
1992-04-29 |
British Tech Group |
Treatment of fibrotic disorders
|
US5869462A
(en)
|
1992-09-10 |
1999-02-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
US5821234A
(en)
|
1992-09-10 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
AU5587094A
(en)
|
1992-10-26 |
1994-05-24 |
Kirin Brewery Company, Limited |
Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
|
EP0669833B1
(en)
|
1992-10-29 |
2002-06-12 |
Celtrix Pharmaceuticals, Inc. |
Type ii tgf-beta-binding receptor fragment as therapeutic agent
|
AU5541094A
(en)
|
1992-10-30 |
1994-05-24 |
Consejo Superior De Investigaciones Cientificas |
Compositions and methods for modifying the regulatory activity of tgf-beta
|
US5830847A
(en)
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
JP3555952B2
(ja)
|
1993-04-30 |
2004-08-18 |
バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング |
トランスフォーミング成長因子−β(TGF‐β)の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
|
WO1995000103A2
(en)
|
1993-06-15 |
1995-01-05 |
Il-Yang Pharm. Co., Ltd. |
Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
|
AU8016894A
(en)
|
1993-10-15 |
1995-05-04 |
La Jolla Cancer Research Foundation |
Betaglycan polypeptides having tgf-beta binding activity
|
ATE208494T1
(de)
|
1994-05-04 |
2001-11-15 |
Mount Sinai Hospital Corp |
Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
|
US5772995A
(en)
|
1994-07-18 |
1998-06-30 |
Sidney Kimmel Cancer Center |
Compositions and methods for enhanced tumor cell immunity in vivo
|
CA2156767A1
(en)
|
1994-08-25 |
1996-02-26 |
Kenichi Matsunaga |
Binding agent for growth factor
|
JPH08119984A
(ja)
|
1994-08-31 |
1996-05-14 |
Nkk Corp |
ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
|
US5824655A
(en)
|
1995-02-15 |
1998-10-20 |
The University Of Utah |
Anti-transforming growth factor-β gene therapy
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
AU2749697A
(en)
|
1996-04-30 |
1997-11-19 |
Genzyme Corporation |
Use of prolactin as a tgf-beta antagonist
|
JPH1067674A
(ja)
|
1996-06-19 |
1998-03-10 |
Advanced Sukin Res Kenkyusho:Kk |
細胞外マトリツクスの異常蓄積抑制剤
|
WO1998017304A1
(en)
|
1996-10-25 |
1998-04-30 |
Johnson & Johnson Medical, Inc. |
Anti-fibrotic agent assay
|
DE69838061T2
(de)
|
1997-04-18 |
2008-03-13 |
Biogen Idec Ma Inc., Cambridge |
Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US6468522B1
(en)
|
1999-07-22 |
2002-10-22 |
University Of Medicine And Dentistry Of New Jersey |
Controlled release of thioamide moiety-containing therapeutic agents
|
US6521266B1
(en)
|
1999-09-23 |
2003-02-18 |
Morris A. Mann |
Composition for growth hormone production and release, appetite suppression, and methods related thereto
|
WO2002062787A1
(en)
|
2001-02-02 |
2002-08-15 |
Glaxo Group Limited |
Pyrazoles as tgf inhibitors
|
ATE291020T1
(de)
|
2001-02-02 |
2005-04-15 |
Smithkline Beecham Corp |
Pyrazolderivate gegen tgf überexprimierung
|
GB0102668D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102665D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102672D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102673D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
ES2289116T3
(es)
|
2001-05-24 |
2008-02-01 |
Eli Lilly And Company |
Nuevos derivados de pirrol como agentes farmaceuticos.
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
JP2005530800A
(ja)
|
2002-05-15 |
2005-10-13 |
スミスクライン・ビーチャム・コーポレイション |
ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
|
WO2003097615A1
(en)
|
2002-05-17 |
2003-11-27 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
|
WO2004010929A2
(en)
|
2002-07-25 |
2004-02-05 |
Scios, Inc. |
METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
|
GB0217786D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Compounds
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
AU2003272324A1
(en)
|
2002-09-10 |
2004-04-30 |
Scios Inc. |
INHIBITORS OF TFGBeta
|
WO2004026871A1
(en)
|
2002-09-17 |
2004-04-01 |
Eli Lilly And Company |
Novel pyrazolopyridine derivatves as pharmaceutical agents
|
WO2004026302A1
(en)
|
2002-09-19 |
2004-04-01 |
Eli Lilly And Company |
Methods of inhibiting tgf beta with substituted pyrazoles
|
US20040127575A1
(en)
|
2002-11-22 |
2004-07-01 |
Feng Ying |
Method for counteracting a pathologic change in the beta-adrenergic pathway
|
EP1578749A2
(en)
|
2002-11-22 |
2005-09-28 |
Eli Lilly And Company |
Pyrazoloazepine compounds as pharmaceutical agents
|
US20040138188A1
(en)
|
2002-11-22 |
2004-07-15 |
Higgins Linda S. |
Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
|
UA80571C2
(en)
|
2002-11-22 |
2007-10-10 |
Lilly Co Eli |
Quinolinyl-pyrrolopyrazoles
|
WO2004050659A1
(en)
|
2002-11-27 |
2004-06-17 |
Eli Lilly And Company |
Novel compounds as pharmaceutical agents
|
CA2513086A1
(en)
|
2002-12-19 |
2004-07-08 |
Scios Inc. |
Treatment of obesity and associated conditions with tgf-.beta. inhibitors
|
CL2004000234A1
(es)
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
WO2004087056A2
(en)
|
2003-03-28 |
2004-10-14 |
Scios Inc. |
BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
|
EP1646655A2
(en)
|
2003-07-09 |
2006-04-19 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
WO2005065691A1
(en)
|
2003-12-24 |
2005-07-21 |
Scios, Inc. |
Treatment of malignant gliomas with tgf-beta inhibitors
|
EP1723146A1
(en)
|
2004-03-01 |
2006-11-22 |
Eli Lilly And Company |
Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
|
ZA200608130B
(en)
|
2004-03-31 |
2008-12-31 |
Genentech Inc |
Humanized anti-TGF-beta antibodies
|
DE102004019253A1
(de)
|
2004-04-16 |
2005-11-10 |
Codewrights Gmbh |
Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
|
CA2578630A1
(en)
|
2004-08-31 |
2006-03-09 |
Wen-Cherng Lee |
Pyrimidinylimidazoles as tgf-beta inhibitors
|
AU2005280167A1
(en)
|
2004-08-31 |
2006-03-09 |
Biogen Idec Ma Inc. |
Pyrimidinylpyrazoles as TGF-beta inhibitors
|
US7511056B2
(en)
|
2004-11-10 |
2009-03-31 |
Eli Lilly And Company |
TGF-β inhibitors
|
LT1850873T
(lt)
|
2005-02-08 |
2019-04-10 |
Genzyme Corporation |
Antikūnas prieš tgf beta
|
HUE049307T2
(hu)
|
2006-01-27 |
2020-09-28 |
Univ California |
Bélben oldódó bevonattal ellátott ciszteamin-bitartrát és cisztamin
|
JP5220025B2
(ja)
|
2006-12-04 |
2013-06-26 |
プロメディオール, インコーポレイテッド |
線維症疾患を処置するための併用療法
|
CN104825430B
(zh)
|
2007-11-30 |
2018-05-04 |
加利福尼亚大学董事会 |
使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法
|